CN105223364A - Serum SHBG albumen is as serum of tuberculosis patients mark and application thereof - Google Patents

Serum SHBG albumen is as serum of tuberculosis patients mark and application thereof Download PDF

Info

Publication number
CN105223364A
CN105223364A CN201510653780.4A CN201510653780A CN105223364A CN 105223364 A CN105223364 A CN 105223364A CN 201510653780 A CN201510653780 A CN 201510653780A CN 105223364 A CN105223364 A CN 105223364A
Authority
CN
China
Prior art keywords
serum
tuberculosis
shbg
albumen
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510653780.4A
Other languages
Chinese (zh)
Other versions
CN105223364B (en
Inventor
何敏
李翠萍
何晓
李洪涛
臧宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangxi Medical University
Original Assignee
Guangxi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangxi Medical University filed Critical Guangxi Medical University
Priority to CN201510653780.4A priority Critical patent/CN105223364B/en
Publication of CN105223364A publication Critical patent/CN105223364A/en
Application granted granted Critical
Publication of CN105223364B publication Critical patent/CN105223364B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Plasma & Fusion (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A kind of serum SHBG (Sex? hormone-binding? globulin) albumen is as serum of tuberculosis patients mark and application thereof, described serum SHBG albumen is cloudy in painting, in Smear positive tuberculosis and Drug resistant pulmonary tubeculosis patients serum, expression obviously increases, iTRAQ can be utilized in conjunction with MALDI-TOF/MS technology for detection, Mass Spectrometer Method SHBG albumen 5 peptide sections are cloudy in painting, in Smear positive tuberculosis and Drug resistant pulmonary tubeculosis patients serum, expression is apparently higher than expression in the serum of pneumonia patient and normal person, ELISA and immunohistochemistry also verify SHBG albumen high expressed in serum of tuberculosis patients and tissue.Be applicable to the auxiliary detection of pulmonary tuberculosis serum, study of incident mechanism and anti-tuberculosis drugs exploitation.

Description

Serum SHBG albumen is as serum of tuberculosis patients mark and application thereof
Technical field
The invention belongs to biological technical field, relate to a kind of application of blood serum designated object, be specially a kind of serum SHBG albumen as serum of tuberculosis patients mark and application thereof.
Background technology
Tuberculosis is the chronic infectious disease caused by mycobacterium tuberculosis infection, 4 ~ 8 weeks latent period, wherein 80% occurs in lung.China belongs to one of 22 tuberculosis high burden countries in the whole world, number of patients is only second to India, occupy second place of the world, except number of patients is many, the order of severity of China's drug resistance of tuberculosis is only second to Russia in the world, drug resistance is spread unchecked and Tubercufosis control will be made to turn back to without the chemotherapy epoch, and the world today about has the tuberculosis patient of 2/3rds to be among the danger of generation Drug-fast case.Therefore, tuberculosis and resistant tuberculosis have become the serious public health of China and social concern.Because Sputum smears routine clinical at present and Sputum culturing detect the method for tubercle bacillus, there is the problems such as the low and/or incubation time of recall rate is long, far can not meet the demand of clinical detection; There is resistance, the spinoffs such as liver damage, gastrointestinal discomfort, allergy in simultaneously clinical at present anti-tuberculosis drugs treatment, and anti-scarring agent repairs focus ability, the problems such as sequelae, therefore, develop new disease marker, significant to control lungy.In recent years, along with the develop rapidly of mass-spectrometric technique and going deep into of proteomics research, create serum quantitative proteomics new technology, this technology is intended to apply the mark in mass-spectrometric technique screening and identification various disease circulation serum, this technology is utilized to have been found that and determine many new disease markers, for disclosing the mechanism of causing a disease of disease further, guide the discovery of new drug targets to provide important clue, the present invention is exactly the new discovery of serum quantitative proteomics technology in tuberculosis research.
Summary of the invention
The object of this invention is to provide a kind of serum SHBG albumen as serum of tuberculosis patients mark and application thereof, solve the problem that recall rate is low and/or incubation time is long that prior art exists, solve anti-tuberculosis drugs treatment clinical at present simultaneously and there is resistance, the spinoffs such as liver damage, gastrointestinal discomfort, allergy, and anti-scarring agent repairs focus ability, the problem of sequelae.Be applicable to pulmonary tuberculosis serum auxiliary detection, study of incident mechanism and anti-tuberculosis drugs exploitation.
Technical scheme of the present invention is: a kind of serum SHBG (Sexhormone-bindingglobulin) albumen is as serum of tuberculosis patients mark, utilize iTRAQ (isobarictagsforrelativeandabsolutequantitation, iTRAQ) in conjunction with MALDI-TOF/MS technology for detection smear negative tuberculosis patient, Smear positive tuberculosis patient, drug-resistant pulmonary tuberculosis patients, the serum of pneumonia patient and normal person, SHBG albumen is cloudy in painting, in Smear positive tuberculosis and Drug resistant pulmonary tubeculosis patients serum, expression is apparently higher than expression in the serum of pneumonia patient and normal person, ELISA and immunohistochemistry also verify SHBG albumen high expressed in serum of tuberculosis patients and tissue.
Described SHBG albumen high expressed in serum of tuberculosis patients and tissue refers to that following 5 peptide section expressions increase: IALGGLLFPASNLR, QAEISASAPTSLR, LPLVPALDGCLR, SCDVESNPGIFLPPGTQAEFNLR, WHQVEVK.
Remarkable result of the present invention is:
Adopt the quantitative proteomics marked based on iTRAQ to comprehensive and systematic research lungy, obtain a kind of serum SHBG albumen as tuberculosis patient blood serum designated object, this mark is through the serum ELISA of large sample and immunohistochemical checking, result is more reliable, can be clinical practice and provides valuable information.
Accompanying drawing explanation
The relative quantitative assay figure of the iTRAQ of Fig. 1 .SHBG
The relative quantitative assay figure of the iTRAQ of SCDVESNPGIFLPPGTQAEFNLR peptide section, with normal person and pneumonia ratio, this peptide section is obvious high expressed in pulmonary tuberculosis serum.
Fig. 2 .ELISA detects the expression figure of SHBG
Healthycontrol: normal control, Pneumonia: pneumonia, SNP-TB: smear negative tuberculosis, DR-TB: drug Resistant Pulmonary Tuberculosis is sick, SPP-TB: pulmonary tuberculosis, ELISA detect the expression of serum SHBG, compare with pneumonia with normal control, the expression of SHBG albumen smear negative tuberculosis patient, obvious high expressed in drug-resistant pulmonary tuberculosis patients, Smear positive tuberculosis patients serum.
Fig. 3. immunohistochemical assay detects the expression of SHBG albumen
The expression of Immunohistochemical detection SHBG albumen in tuberculosis and control tissue.With control group ratio, SHBG albumen is obvious high expressed in pulmonary tuberculosis tissue.
Embodiment
Below by way of specific embodiment, technical scheme of the present invention is further described.
Embodiment 1
Serum Quantitative Western group technique detection SHBG albumen five peptide sections are expressed and are increased in tuberculosis patient serum
1. detect sample: multi-drug resistance tuberculosis, be coated with cloudy tuberculosis, sputum smear positive TB, pneumonia patient and normal control serum each 10 example.Early morning on an empty stomach gathers 2mL whole blood, and 4 DEG C of standing 1-2h treat that serum is separated out in blood clotting, and the centrifugal 10min of 3000g collects supernatant, deposit after packing on ice to-80 DEG C for subsequent use.
2. detection method: (1) removes high-abundance proteins: according to multiple affine removal system human14 chromatographic column operation instructions, removes high-abundant protein from serum, is concentrated by the cut freeze dryer collected.(2) desalination and protein content detect: except the 3000MWCO ultra-filtration centrifuge tube of the serum after high-abundance proteins, add 50mmol/LpH8.5 triethylamine bicarbonate buffer, 3 times repeatedly, desalination and collection protein fragments; Adopt BCA method to measure serum albumin content, often organize low-abundance protein and get 100 μ g/ and manage, freeze-drying.(3) proteolysis and mark iTRAQ: dry sample is added trypsase, and 37 DEG C of digestion are spent the night; After enzymolysis sample vacuum drying, be dissolved in iTRAQ solution damping fluid; ITRAQ reagent 113,117,118,119,120 marks normal healthy controls group, Drug-fast case group respectively, is coated with positive group, is coated with cloudy group and pneumonia group serum protein antioxidant peptide, and the sample after mark removes salt plug desalination through C18spincolumn, freeze-drying.(4) off-line two-dimensional HPLC separation and some target: dry mark sample loading buffer A (10mmol/LKH2PO4,25%CAN, pH2.7) redissolve and dilute 10 times, be loaded to SCX prepacked column, after sample-loading buffer A washs, with the buffer B stepwise elution being respectively 35,50,75,100,125,150,175,200,250 and 300mmol/L containing KCl concentration, collect the polypeptide of wash-out under different gradient concentration condition.Carry out the gradient elution of anti-phase C18 post after each component Sample Dilution collected and put target.(5) mass spectrophotometry and data processing: the tandem mass spectrum marking peptide section is identified and relative quantitative assay adopts the 5800MALDI-TOF/TOF protein analyzer of ABI company, analytical data of mass spectrum ProteinPilot2.0 carries out retrieval qualification albumen to SWISSPROT database, report degree of confidence higher than 95% albumen, each group detects data and 113 and reports that the integrating peak areas of ion carries out relative quantitative assay simultaneously, selects the result of P≤0.05 to report.(6) statistical procedures: application SPSS14.0 software carries out statistical analysis, and continuous data represents with mean ± SD, and the comparison between two sample averages adopts t inspection, with P≤0.05 for difference has statistical significance.
3. testing result: mass spectrum identifies the unique peptide section IALGGLLFPASNLR of 5, SHBG albumen altogether, QAEISASAPTSLR, LPLVPALDGCLR, SCDVESNPGIFLPPGTQAEFNLR, WHQVEVK, overall coverage rate 22.4%, 117/113=5.706,118/113=6.0681,119/113=11.1686, P < 0.05; 120/113=1.0864, P > 0.05.SHBG albumen expression in resistance tuberculosis, painting yin constipation core and sputum smear positive TB human serum obviously increases.As shown in Figure 1.
Embodiment 2
Preparation is containing IALGGLLFPASNLR, QAEISASAPTSLR, LPLVPALDGCLR, SCDVESNPGIFLPPGTQAEFNLR, 5 peptide section SHBG protein antibodies such as WHQVEVK, utilize this antibody to carry out ELISA detection, find that SHBG albumen increases at tuberculosis patient serum expression.
1. sample: collect 24 routine normal healthy controls, 15 routine pneumonia patients, 160 routine tuberculosis patient serum, wherein Drug-fast case 35 example, be coated with cloudy tuberculosis 70 example, sputum smear positive TB 55 example.
2. detection method: 1. application of sample: set blank well, blank control wells does not add sample and enzyme marking reagent, and all the other are identical, the gauge orifice of step operation, testing sample hole respectively.Added the sample diluting liquid RD1-75 of 100 μ l at enzyme mark bag by Kong Zhongxian each on plate, bottom ELISA Plate hole, then add the blank of 50 μ l, titer and testing sample, the final dilutability of sample is 100 times.Do not touch hole wall as far as possible, rock mixing gently.2. incubation: use the rearmounted incubation at room temperature of shrouding film shrouding 3 hours.3. dosing: by for subsequent use after 25 times of concentrated cleaning solution distilled water 25 times dilution.4. wash: throw off shrouding film, discard liquid, dry, every hole 400 μ l cleansing solution, leave standstill and discard after 30 seconds, so repeat 4 times, pat dry.5. incubation: every hole adds SHBG bond 200 μ l, with the rearmounted incubation at room temperature of shrouding film shrouding 1 hour.6. wash: operation is same 4..7. develop the color: every hole first adds substrate solution 200 μ l, puts incubation at room temperature half an hour, shakes mixing gently, 37 DEG C of lucifuge colour developings.8. stop: every hole adds stop buffer 50 μ l, cessation reaction, now blue standing turns yellow.9. measure: the absorbance sequentially measuring each hole with blank air-conditioning zero, 450nm wavelength, i.e. OD value.Mensuration should be carried out within 15 minutes after adding stop buffer.Result: Quality Control point blank well presents colourless, OD value when being 0, can judge testing result.
3. result: SHBG albumen is respectively 181.76 ± 200.09 in multi-drug resistance tuberculosis people, sputum smear positive TB people, the concentration (nmol/L) be coated with in cloudy tuberculosis patient, pneumonia patient and normal control serum, 160.43 ± 75.45,159.75 ± 75.47,60.63 ± 59.38,33.39 ± 34.24, p<0.0001, in tuberculosis patient serum, expression obviously increases, as shown in Figure 2.
Embodiment 3
Preparation is containing IALGGLLFPASNLR, QAEISASAPTSLR, LPLVPALDGCLR, SCDVESNPGIFLPPGTQAEFNLR, the SHBG albumen primary antibodie of 5 peptide sections such as WHQVEVK, utilizes this primary antibodie to carry out Immunohistochemical detection, finds SHBG albumen high expressed in tuberculosis.
1. sample: utilize USBiomax commercialization organization chip to detect the expression of SHBG, wherein comprise 40 routine tuberculosis, 10 routine control tissue, control tissue is normal lung tissue and cancerous lung tissue.
2. experimental procedure: 1. dewax: successively microslide is put into dimethylbenzene-dimethylbenzene-100% alcohol-100% alcohol-95% alcohol-90% alcohol-80% alcohol-70% alcohol.Put 10min above in two reagent, after 6 reagent be 5min.2. antigen retrieval: rinse a period of time after dewaxing in clear water, adds 3%H 2o 2soak 10min, then outwell H 2o 2, in clear water, washing twice, then add citrate buffer solution, put into micro-wave oven moderate heat boiling 3min, being generally just cooled to room temperature to seething with excitement, and then boiling once, is cooled to room temperature.3. serum is closed: after being cooled to room temperature, outwelled by citrate buffer solution, wash 2 times, and microslide is placed in PBS 5min, wash 2 times, dry the PBS liquid around tissue, and horse back adds serum, then puts into room temperature or 37 DEG C of incubator half an hour.4. add primary antibodie: taken out by the microslide in incubator, dry the serum around microslide reverse side and face weave, add primary antibodie with thieving paper, control experiment just adds PBS at the tissue of contrast.Preserve in 4 DEG C of refrigerators after adding primary antibodie and spend the night.5. add two to resist: microslide is taken out from refrigerator, puts into PBS and wash 3 times, each 5min, after drying the PBS around tissue, add that two resist, be placed on half an hour in room temperature or 37 DEG C of incubators.6. slice, thin piece is taken out from incubator, put into PBS and wash 3 times, each 5min, drip reagent solution C, be then placed in room temperature or 37 DEG C of incubator 10-15min.7. add developer: taken out from incubator by slice, thin piece, put into PBS and wash 3 times, each 5min, after drying the PBS around tissue, add developer.The configuration of developer: add 1 developer A in 1ml water, shake up, then adds 1 developer B, shakes up, then adds 1 developer C, shakes up.8. redye: after the slice, thin piece clear water after colour developing is rinsed a period of time, be soaked in haematine and dye.9. mounting: drop in neutral gum and organize side, then cover with cover glass, first will set level side, then put down opposite side gently, in order to avoid produce bubble, seals slice, thin piece and is placed in vent cabinet and dries.
3. result: SHBG protein expression total positives in 40 routine tuberculosis, in 10 routine control tissue, SHBG expresses total negative, as shown in Figure 3.

Claims (2)

1. serum SHBG (Sexhormone-bindingglobulin) albumen is as serum of tuberculosis patients mark, it is characterized in that, mankind SHBG is the homodimer plasma glycoprotein synthesized by liver cell, the homodimer that complete mankind SHBG molecule is made up of on all four 2 monomers of amino acid sequence, every bar monomer is made up of 373 amino acid residues, molecular weight is 40499D, utilize iTRAQ (isobarictagsforrelativeandabsolutequantitation, iTRAQ) in conjunction with MALDI-TOF/MS technology for detection smear negative tuberculosis people, Smear positive tuberculosis patient, drug-resistant pulmonary tuberculosis patients, the serum of pneumonia patient and normal person, SHBG albumen is cloudy in painting, in Smear positive tuberculosis and Drug resistant pulmonary tubeculosis patients serum, expression is apparently higher than expression in the serum of pneumonia patient and normal person, ELISA and immunohistochemistry also verify SHBG albumen high expressed in serum of tuberculosis patients and tissue.
2. serum SHBG (Sexhormone-bindingglobulin) albumen according to claim 1 is as serum of tuberculosis patients mark, it is characterized in that, described SHBG albumen high expressed in serum of tuberculosis patients refers to that following 5 peptide section expressions increase:
IALGGLLFPASNLR
QAEISASAPTSLR
LPLVPALDGCLR
SCDVESNPGIFLPPGTQAEFNLR
WHQVEVK。
CN201510653780.4A 2015-10-10 2015-10-10 Serum SHBG albumen is as pulmonary tuberculosis blood serum designated object and its application Active CN105223364B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510653780.4A CN105223364B (en) 2015-10-10 2015-10-10 Serum SHBG albumen is as pulmonary tuberculosis blood serum designated object and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510653780.4A CN105223364B (en) 2015-10-10 2015-10-10 Serum SHBG albumen is as pulmonary tuberculosis blood serum designated object and its application

Publications (2)

Publication Number Publication Date
CN105223364A true CN105223364A (en) 2016-01-06
CN105223364B CN105223364B (en) 2018-02-23

Family

ID=54992432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510653780.4A Active CN105223364B (en) 2015-10-10 2015-10-10 Serum SHBG albumen is as pulmonary tuberculosis blood serum designated object and its application

Country Status (1)

Country Link
CN (1) CN105223364B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107727729A (en) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 A kind of method for building up of OA candidate markers diagnostic model
CN108226515A (en) * 2017-11-28 2018-06-29 泰州泽成生物技术有限公司 A kind of kit and its test method for measuring sex hormone binding globulin content
CN109030834A (en) * 2018-08-11 2018-12-18 南京市儿童医院 A method of the aortic coaractation marker detection based on proteomics
CN109852629A (en) * 2019-02-22 2019-06-07 广西医科大学 A kind of expression and purification method of recombined human sex hormone binding globulin N-terminal 51-218aa
CN110437322A (en) * 2019-08-30 2019-11-12 上海市肺科医院 A kind of marker and its application for diagnosis of tuberculosis
TWI682175B (en) * 2018-04-16 2020-01-11 臺北醫學大學 Method of gastric cancer diagnosis
WO2023185068A1 (en) * 2022-03-29 2023-10-05 浙江苏可安药业有限公司 Serum metabolic markers for detecting drug-resistant pulmonary tuberculosis and kit thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803493A (en) * 2010-01-11 2012-11-28 库尔纳公司 Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
CN103065065A (en) * 2012-11-18 2013-04-24 浙江大学 Active tuberculosis differential expression protein profile model and building method thereof
WO2014133855A1 (en) * 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803493A (en) * 2010-01-11 2012-11-28 库尔纳公司 Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
CN103065065A (en) * 2012-11-18 2013-04-24 浙江大学 Active tuberculosis differential expression protein profile model and building method thereof
WO2014133855A1 (en) * 2013-02-28 2014-09-04 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANDAN XU ET AL: "Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS", 《PROTEOMICS》 *
JOHANNES D. VELDHUIS ET AL: "Immunologic and mass-spectrometric estimates of SHBG concentrations in healthy women", 《METABOLISM》 *
TRANG N.LE ET AL: "Sex hormone-binding globulin and type 2 diabetes mellitus", 《CELL PRESS》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107727729A (en) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 A kind of method for building up of OA candidate markers diagnostic model
CN108226515A (en) * 2017-11-28 2018-06-29 泰州泽成生物技术有限公司 A kind of kit and its test method for measuring sex hormone binding globulin content
TWI682175B (en) * 2018-04-16 2020-01-11 臺北醫學大學 Method of gastric cancer diagnosis
CN109030834A (en) * 2018-08-11 2018-12-18 南京市儿童医院 A method of the aortic coaractation marker detection based on proteomics
CN109852629A (en) * 2019-02-22 2019-06-07 广西医科大学 A kind of expression and purification method of recombined human sex hormone binding globulin N-terminal 51-218aa
CN110437322A (en) * 2019-08-30 2019-11-12 上海市肺科医院 A kind of marker and its application for diagnosis of tuberculosis
CN110437322B (en) * 2019-08-30 2021-11-30 上海市肺科医院 Marker for tuberculosis diagnosis and application thereof
WO2023185068A1 (en) * 2022-03-29 2023-10-05 浙江苏可安药业有限公司 Serum metabolic markers for detecting drug-resistant pulmonary tuberculosis and kit thereof

Also Published As

Publication number Publication date
CN105223364B (en) 2018-02-23

Similar Documents

Publication Publication Date Title
CN105223364A (en) Serum SHBG albumen is as serum of tuberculosis patients mark and application thereof
CN101611314B (en) Diagnosis and risk stratification by means of novel marker CT-proADM
Lee et al. Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery
CN105301259A (en) Serum RBP4 (retinol binding protein 4) albumen as liver cancer patient serum marker and application of serum RBP4 albumen
CN106932589A (en) Determine kit of human serum RBP ELISA content and preparation method thereof
Hakimi et al. Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label‐free quantitative data‐independent LC‐MS
CN105572355A (en) Biomarker for detecting esophagus cancer
EP3216460B1 (en) Antigen polypeptide for detecting plasma immunological marker-vegfr1 autoantibody and use thereof
Chutipongtanate et al. Plasma prefractionation methods for proteomic analysis and perspectives in clinical applications
Nilsen et al. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers
CN107255711B (en) Osteopontin is used to prepare or screens the purposes of acute-on-chronic liver failure diagnostic reagent
CN104215777A (en) Method for detecting hemoglobin-combined phosphorylated alpha-synuclein
CN110174519B (en) Confluent-detection type erythrocyte blood type irregular antibody detection kit based on solid-phase agglutination technology and preparation method thereof
CN109306368A (en) Application of the Thp-1 epicyte protein Annexin A2 in Ac-Gal-1 is apoptosis-induced
CN105424941A (en) AKR1B10 protein and reagent kit for liver cirrhosis diagnosis
Aita et al. Salivary proteomic analysis in asymptomatic and symptomatic SARS-CoV-2 infection: Innate immunity, taste perception and FABP5 proteins make the difference
CN108982868B (en) Application of nucleosomal protein SP110 and kit containing same in preparation of alcoholic cardiomyopathy early diagnosis reagent
CN203798811U (en) Hypophysoma multi-hormone combined detection chip
CN108287239B (en) Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit
CN108663522B (en) Bladder cancer detection kit
CN104292322A (en) Specific autoantigen of primary biliary cirrhosis (PBC) and application thereof
Biosa et al. Proteomic characterization of Echinococcus granulosus sensu stricto, Taenia hydatigena and Taenia multiceps metacestode cyst fluids
Cho et al. Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry
CN109116023A (en) A kind of lung cancer marker anti-MM P12 autoantibody and its application
CN109085355A (en) Serum protein markers combine the application in screening lung cancer and diagnosis and treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant